Because most metaplastic breast carcinomas overexpress EGFR without gene amplification, further studies to evaluate EGFR activating mutations are warranted.
Although several phase III studies in genotypically defined groups of patients are already available, further prospective studies assessing the role of uncommon EGFR mutations are warranted.
The isolates were not available for sequencing, but, further studies that look at the presence of these low level mutations are warranted.
Furthermore, PIK3CA mutations were always found in esophageal cancer [ 23, 24] and further functional analyses of the mutations are warranted to determine whether or not they may be potentially useful targets of therapy for esophageal cancer [ 25].
Thus careful evaluation of historical functional analysis of classical mutations is warranted.
We biologically validate the potential impact of deletions in SLC22A16 at 6q21 and future biological analysis of additional CNAs and mutations is warranted.
We sought to ascertain the prevalence of PALB2 mutations in these women due to the high estimated breast cancer risk associated with at least some PALB2 mutations and to further consider if clinical testing for these mutations is warranted.
In this regard, greater understanding of the changing biology of E2F1 especially in the context of cancer-specific mutations is warranted to ensure that E2F1 activity can be leveraged for the benefit of melanoma patients.
Further studies of mutations in NSCLC are warranted to facilitate more specific diagnoses and guide treatment.
Future mechanistic studies of the somatic mutations reported herein are warranted.
